ImmuneOnco Biopharmaceuticals (Shanghai) Inc. on a voluntary basis to informed shareholders and potential investors of the Company about the latest business development of the Group. The board of directors of the Company announced that: (i) The Group has recently completed the enrollment of patients for the Phase I dose-escalation study of IMM2510. The recommended Phase II dose (RP2D) was determined to be 20 mg/kg administered once every two weeks (Q2W); and (ii) The Group has recently completed the enrollment of patients for the Phase I dose-escalation study of IMM27M.

The RP2D was determined to be 5 mg/kg administered once every three weeks (Q3W).